Latest Antivirals Stories
Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat.
New study identifies potential alternatives to Gilead's Sovaldi PHILADELPHIA, July 28, 2014 /PRNewswire/ -- The Intellectual
HIV-infected patients also infected with hepatitis C virus (HCV) who received a combination of the medications sofosbuvir plus ribavirin had high rates of sustained HCV virologic response 12 weeks after cessation of therapy.
Unprecedented Growth Will be Fuelled by Rapid Uptake of All-Oral, Interferon-Free Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/
Chronic hepatitis C virus infections are among the most common reasons for liver transplants.
Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON,
NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free
GIA announces the release of a comprehensive global report on Growth Factors (Blood and Tissue) markets.
NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the
ResolveHerpes is Designed to Boost the Body's Immune System and Allow it to Clear Out the Herpes Viruses HSV-1 and HSV-2 LOS ANGELES, June 11, 2014 /PRNewswire-iReach/ -- Resolve Herpes,
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.